The results showed that the vaccine was well tolerated and had no dose-dependent toxicity, and the T-cell response to one or two vaccine antigens tripled in 15 of the 18 patients who received treatment.374 Phase I clinical trials of the MVA-EL vaccine comprising 16 NPC patients in the UK also showed that 8 of 14 patients who received treatment had increased CD4+ and CD8+ T-cell responses to one or both antigens, and immunophenotypic analysis confirmed that vaccination induced differentiation and functional diversity of EBNA1- and LMP2-specific CD4+ and CD8+. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.